Not that it matters, but patients were recruited to the EMD AML...

Not that it matters, but patients were recruited to the EMD AML trial, the problem was that clinicians would not screen their patients for EMD before they failed their current treatment preventing treatment with bisantrene. The trial was planned on the basis that clinicians would screen in advance of failure (this is what they told us they would do so this was a reasonable assumption), but unfortunately this is not what they did in practice. Of course EMD AML still remains a very attractive opportunity when clinicians decide that screening, rather than guessing, is a good idea.

The whole RC110/RC220 situation is complex. The development of RC220 was difficult to predict in advance, but once invented it changed everything. Pushing ahead with RC110 when you have RC220 makes little sense, but waiting for RC220 to be ready meant some short term pain to the SP. You are right that we are through the “valley of death” and we are now moving forward again with a vastly superior formulation.